July 24, 2023
A total of seven medicines hauled in sales exceeding 100 billion yen in Japan in FY2022, the largest number since Jiho started taking a tally in FY2005. The COVID-19 therapy Ronapreve (casirivimab/imdevimab) earned by far the biggest revenue, at over...read more